Journal Article

Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)

Ledermann, Jonathan A, Hirschowitz, Lynn, McCluggage, W Glenn, Hollema, Harry, Vang, Russell, Mikami, Yoshiki, Clarke, Blaise A, Davidson, Ben, Judge, Meagan J, Stewart, Colin JR, Matias-Guiu, Xavier, Gilks, C Blake

2015

Overview

A comprehensive pathological report is essential for optimal patient management, cancer staging and prognostication. In many countries, proforma reports are used but these vary in their content. The International Collaboration on Cancer Reporting (ICCR) is an alliance formed by the Royal College of Pathologists of Australasia, the Royal College of Pathologists of the United Kingdom, the College of American Pathologists, the Canadian Partnership Against Cancer and the European Society of Pathology, with the aim of developing an evidence-based reporting data set for each cancer site. This will reduce the global burden of cancer data set development and reduplication of effort by different international institutions that commission, publish and maintain standardised cancer reporting data sets. The resultant standardisation of cancer reporting will benefit not only those countries directly involved in the collaboration but also others not in a position to develop their own data sets. We describe the development of a cancer data set by the ICCR expert panel for the reporting of primary ovarian, fallopian tube and peritoneal carcinoma and present the ‘required’ and ‘recommended’ elements to be included in the report with an explanatory commentary. This data set encompasses the recent International Federation of Obstetricians and Gynaecologists staging system for these neoplasms and the updated World Health Organisation Classification of Tumours of the Female Reproductive Organs. The data set also addresses issues about site assignment of the primary tumour in high-grade serous carcinomas and proposes a scoring system for the assessment of tumour response to neoadjuvant chemotherapy. The widespread implementation of this data set will facilitate consistent and accurate data collection, comparison of epidemiological and pathological parameters between different populations, facilitate research and hopefully will result in improved patient management.

• Publisher: Nature Publishing Group US,Elsevier Limited
• Subject: 13/51 / 692/420 / 692/420/755 / 692/699 / 692/699/67/1517/1709 / Alliances / Biomarkers, Tumor - analysis / Biomarkers, Tumor - genetics / Biopsy - standards / Cancer / Carcinoma - chemistry / Carcinoma - drug therapy / Carcinoma - genetics / Carcinoma - pathology / Carcinoma - surgery / Chemotherapy, Adjuvant / Collaboration / Datasets / Diagnosis, Differential / Fallopian Tube Neoplasms - chemistry / Fallopian Tube Neoplasms - drug therapy / Fallopian Tube Neoplasms - genetics / Fallopian Tube Neoplasms - pathology / Fallopian Tube Neoplasms - surgery / Fallopian tubes / Female / Gynecology / Hospitals / Humans / Immunohistochemistry - standards / Laboratory Medicine / Libraries / Medicine / Medicine & Public Health / Molecular Diagnostic Techniques - standards / Neoadjuvant Therapy / Neoplasm Grading / Neoplasm Staging / original-article / Ovarian Neoplasms - chemistry / Ovarian Neoplasms - drug therapy / Ovarian Neoplasms - genetics / Ovarian Neoplasms - pathology / Ovarian Neoplasms - surgery / Ovaries / Pathology / Pathology, Clinical - standards / Peritoneal Neoplasms - chemistry / Peritoneal Neoplasms - drug therapy / Peritoneal Neoplasms - genetics / Peritoneal Neoplasms - pathology / Peritoneal Neoplasms - surgery / Predictive Value of Tests / Research Design - standards